The latest data point for LLY's Return on Sales (ROS) in Q4'25 stands at 42.8%, reflecting a robust performance driven by strong operational efficiencies and revenue growth in the pharmaceutical sector. This marks a slight uptick from Q3'25's 41.1%, indicating sustained profitability momentum into the fiscal year's end. Over the period from Q2'23 to Q4'25, ROS exhibits a volatile yet predominantly upward trend, starting at a modest 25.1% and peaking at 42.8%, with notable dips in Q3'23 (4.5%) and Q3'24 (13.9%) likely due to seasonal or cost pressures. Key growth phases include a steady climb from Q4'23 (26.8%) to Q2'24 (31.1%), followed by a resurgence post-Q3'24 to reach highs in Q2'25 (43.6%) and beyond, underscoring LLY's resilience and improving margins in a competitive market. The area chart visualization highlights these fluctuations, with an overall average ROS around 30% signaling positive long-term profitability.